Two of Canada’s leading patient groups, the Gastrointestinal Society and the Canadian Society of Intestinal Research, are calling on patients with inflammatory bowel disease (IBD) to participate in a survey to help identify what’s missing in their care. They are also asking Canadian patients with any inflammatory condition who take biologic/biosimilar medication to provide their opinions.
Inflammatory bowel disease
The first survey, IBD Patients: What’s Missing in Your Care?, seeks to learn more about IBD patients’ experiences and their outlook in current management. The survey, available in English and French, follows a similar questionnaire conducted in 2018, but this time is open to IBD patients worldwide in order to collect a larger and more diverse body of information about the IBD patient community. Participants must have been diagnosed with any type of IBD (Crohn disease, ulcerative colitis, ulcerative proctitis, microscopic colitis, etc.). Visit https://badgut.org/ibd-survey-2019 to learn more and participate in the study.
Use of biologic/biosimilar medications for inflammatory diseases
The second survey, the Canadian Biosimilar Medication Experience, explores the experiences and outlook of Canadian patients who use biologic/biosimilar medications to treat inflammatory bowel disease (Crohn disease or ulcerative colitis), as well as other inflammation-causing diseases such as diabetes, rheumatoid arthritis, cancer, osteoporosis, psoriasis, HIV, multiple sclerosis, or growth deficiencies. This survey follows up on one conducted in 2015. Visit https://badgut.org/biosimilars-survey-2019 to learn more and participate in the study.
Data gathered from both surveys will be used anonymously and in aggregate to shape future programming and to inform discussions with community members, health care professionals, and health policy decision-makers.
For more information about the Gastrointestinal Society and the Canadian Society of Intestinal Research visit www.badgut.org.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org